Integrated analysis of breast cancer cell lines reveals unique signaling pathways

Genome Biology

Volumn 10, Issue 3, 2009, Pages

  Heiser, Laura M ^a   Wang, Nicholas J ^a   Talcott, Carolyn L ^b   Laderoute, Keith R ^b   Knapp, Merrill ^b   Guan, Yinghui ^a   Hu, Zhi ^a   Ziyad, Safiyyah ^a   Weber, Barbara L ^c   Laquerre, Sylvie ^c   Jackson, Jeffrey R ^c   Wooster, Richard F ^c   Kuo, Wen ^a   Gray, Joe W ^a,d   Spellman, Paul T ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b SRI INTERNATIONAL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GSK 1120212; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; P21 ACTIVATED KINASE 1; UNCLASSIFIED DRUG; UO 126; CAVEOLIN 1; INTEGRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; P21 ACTIVATED KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLINICAL INDICATOR; CLUSTER ANALYSIS; COMPUTER PREDICTION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE MAPPING; GENE OVEREXPRESSION; PATIENT SELECTION; PROTEIN INTERACTION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; BIOLOGICAL MODEL; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; P21-ACTIVATED KINASES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 64649098960     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2009-10-3-r31     Document Type: Article

References (101)

1. Albertson DG Collins C McCormick F Gray JW Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369-376. 10.1038/ng1215 12923544
2. Baylin SB Herman JG DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000, 16:168-174. 10.1016/ S0168-9525(99)01971-X 10729832
3. Jones PA Overview of cancer epigenetics. Semin Hematol 2005, 42:S3-8. 10.1053/j.seminhematol.2005.05.001 16015502
4. Knuutila S Autio K Aalto Y Online access to CGH data of DNA sequence copy number changes. Am J Pathol 2000, 157:689. 1850112 10934171
5. Hanahan D Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9 10647931
6. Roberts PJ Der CJ Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422 17496923
7. Murphy LO MacKeigan JP Blenis J A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol 2004, 24:144-153. 303364 14673150 10.1128/MCB.24.1.144-153.2004
8. Coutts AS Murphy LC Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998, 58:4071-4074. 9751612
9. El-Ashry D Miller DL Kharbanda S Lippman ME Kern FG Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997, 15:423-435. 10.1038/sj.onc.1201198 9242379
10. Sivaraman VS Wang H Nuovo GJ Malbon CC Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997, 99:1478-1483. 507966 9119990 10.1172/JCI119309
11. Citri A Yarden Y EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516. 10.1038/nrm1962 16829981
12. Mendelsohn J Baselga J The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565. 10.1038/sj.onc.1204082 11426640
13. Baselga J Tripathy D Mendelsohn J Baughman S Benz CC Dantis L Sklarin NT Seidman AD Hudis CA Moore J Rosen PP Twaddell T Henderson IC Norton L Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744. 8622019
14. Cobleigh MA Vogel CL Tripathy D Robert NJ Scholl S Fehrenbacher L Wolter JM Paton V Shak S Lieberman G Slamon DJ Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648. 10561337
15. Kris MG Ranson M Ferry D Hammond L Averbuch S Ochs J Rowinsky E Phase I study of oral ZD1839 a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity. Clin Cancer Res 1999, 5(Suppl):3749-3750.
16. Ferry D Hammond L Ranson M Kris MG Miller V Murray A Tullo A Feyereislova A Averbuch S Rowinsky E Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), shows evidence of good tolerability and activity: Final results from a Phase I study. Proc Am Soc Clin Oncol 2000, 19:5E.
17. Dudley DT Pang L Decker SJ Bridges AJ Saltiel AR A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995, 92:7686-7689. 41210 7644477 10.1073/pnas.92.17.7686
18. Solit DB Garraway LA Pratilas CA Sawai A Getz G Basso A Ye Q Lobo JM She Y Osman I Golub TR Sebolt-Leopold J Sellers WR Rosen N BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362. 10.1038/nature04304 16273091
19. Thompson N Lyons J Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005, 5:350-356. 10.1016/j.coph.2005.04.007 15955734
20. Yeh TC Marsh V Bernat BA Ballard J Colwell H Evans RJ Parry J Smith D Brandhuber BJ Gross S Marlow A Hurley B Lyssikatos J Lee PA Winkler JD Koch K Wallace E Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583. 10.1158/ 1078-0432.CCR-06-1150 17332304
21. Lapidus RG Nass SJ Davidson NE The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998, 3:85-94. 10.1023/A:1018778403001 10819507
22. Oh DS Troester MA Usary J Hu Z He X Fan C Wu J Carey LA Perou CM Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664. 10.1200/ JCO.2005.03.2755 16505416
23. Perou CM Jeffrey SS Rijn van de M Rees CA Eisen MB Ross DT Pergamenschikov A Williams CF Zhu SX Lee JC Lashkari D Shalon D Brown PO Botstein D Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96:9212-9217. 17759 10430922 10.1073/pnas.96.16.9212
24. Perou CM Sorlie T Eisen MB Rijn van de M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A Williams C Zhu SX Lonning PE Borresen-Dale AL Brown PO Botstein D Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093 10963602
25. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB Rijn van de M Jeffrey SS Thorsen T Quist H Matese JC Brown PO Botstein D Eystein Lonning P Borresen-Dale AL Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566 11553815 10.1073/pnas.191367098
26. Carey LA Dees EC Sawyer L Gatti L Moore DT Collichio F Ollila DW Sartor CI Graham ML Perou CM The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109 17438091
27. Creighton CJ Hilger AM Murthy S Rae JM Chinnaiyan AM El-Ashry D Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006, 66:3903-3911. 10.1158/0008-5472.CAN-05-4363 16585219
28. Chin K DeVries S Fridlyand J Spellman PT Roydasgupta R Kuo WL Lapuk A Neve RM Qian Z Ryder T Chen F Feiler H Tokuyasu T Kingsley C Dairkee S Meng Z Chew K Pinkel D Jain A Ljung BM Esserman L Albertson DG Waldman FM Gray JW Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/ j.ccr.2006.10.009 17157792
29. Fridlyand J Snijders AM Ylstra B Li H Olshen A Segraves R Dairkee S Tokuyasu T Ljung BM Jain AN McLennan J Ziegler J Chin K Devries S Feiler H Gray JW Waldman F Pinkel D Albertson DG Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96. 1459181 16620391 10.1186/1471-2407-6-96
30. Letessier A Sircoulomb F Ginestier C Cervera N Monville F Gelsi-Boyer V Esterni B Geneix J Finetti P Zemmour C Viens P Charafe-Jauffret E Jacquemier J Birnbaum D Chaffanet M Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006, 6:245. 1626089 17040570 10.1186/1471-2407-6-245
31. Wood LD Parsons DW Jones S Lin J Sjoblom T Leary RJ Shen D Boca SM Barber T Ptak J Silliman N Szabo S Dezso Z Ustyanksky V Nikolskaya T Nikolsky Y Karchin R Wilson PA Kaminker JS Zhang Z Croshaw R Willis J Dawson D Shipitsin M Willson JK Sukumar S Polyak K Park BH Pethiyagoda CL Pant PV et al The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113. 10.1126/science.1145720 17932254
32. Bild AH Yao G Chang JT Wang Q Potti A Chasse D Joshi MB Harpole D Lancaster JM Berchuck A Olson JA Jr Marks JR Dressman HK West M Nevins JR Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357. 10.1038/nature04296 16273092
33. Potti A Dressman HK Bild A Riedel RF Chan G Sayer R Cragun J Cottrill H Kelley MJ Petersen R Harpole D Marks J Berchuck A Ginsburg GS Febbo P Lancaster J Nevins JR Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300. 10.1038/nm1491 17057710
34. Nevins JR Potti A Mining gene expression profiles: Expression signatures as cancer phenotypes. Nat Rev Genet 2007, 8:601-609. 10.1038/nrg2137 17607306
35. Eker S Knapp M Laderoute K Lincoln P Meseguer J Sonmez K Pathway logic: symbolic analysis of biological signaling. Pac Symp Biocomput 2002. 400-412. 11928493
36. Talcott C Eker S Knapp M Lincoln P Laderoute K Pathway logic modeling of protein functional domains in signal transduction. Pac Symp Biocomput 2004, 568-580. 14992534
37. Talcott C Formal executable models of cell signaling primatives. 2nd International Symposium On Leveraging Applications of Formal Methods, Verification and Validation: 15-19 November 2006; Paphos, Cyprus APaBS; Springer LNCS; Heidelberg Margaria T 2006, 303-307.
38. Talcott C Symbolic modeling of signal transduction in pathway logic. 2006 Proceedings of the Winter Simulation Conference WSC 2006: December 3-6, 2006; Monterey, CA, USA WSC; USA Perrone LF, Liu J, Lawson BG, Nicol DM, Fujimoto RM 2006, 1656-1665.
39. Hlavacek WS Faeder JR Blinov ML Posner RG Hucka M Fontana W Rules for modeling signal-transduction systems. Sci STKE 2006, 2006:rE6. 10.1126/ stke.3442006re6 16849649
40. Kohn KW Aladjem MI Weinstein JN Pommier Y Molecular interaction maps of bioregulatory networks: A general rubric for systems biology. Mol Biol Cell 2006, 17:1-13. 1345641 16267266 10.1091/mbc.E05-09-0824
41. Baselga J Arteaga CL Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459. 10.1200/JCO.2005.11.890 15753456
42. Yarden Y Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073 11252954
43. Neve RM Chin K Fridlyand J Yeh J Baehner FL Fevr T Clark L Bayani N Coppe JP Tong F Speed T Spellman PT DeVries S Lapuk A Wang NJ Kuo WL Stilwell JL Pinkel D Albertson DG Waldman FM McCormick F Dickson RB Johnson MD Lippman M Ethier S Gazdar A Gray JW A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008 17157791
44. Holst F Stahl PR Ruiz C Hellwinkel O Jehan Z Wendland M Lebeau A Terracciano L Al-Kuraya K Janicke F Sauter G Simon R Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007, 39:655-660. 10.1038/ng2006 17417639
45. Stierer M Rosen H Weber R Hanak H Spona J Tuchler H Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993, 218:13-21. 1242895 8328824 10.1097/ 00000658-199307000-00004
46. Sanger COSMIC Website http://www.sanger.ac.uk/genetics/CGP/cosmic/
47. Kozma SC Bogaard ME Buser K Saurer SM Bos JL Groner B Hynes NE The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987, 15:5963-5971. 306061 3627975 10.1093/nar/15.15.5963
48. Rochlitz CF Scott GK Dodson JM Liu E Dollbaum C Smith HS Benz CC Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989, 49:357-360. 2642738
49. Li J Yen C Liaw D Podsypanina K Bose S Wang SI Puc J Miliaresis C Rodgers L McCombie R Bigner SH Giovanella BC Ittmann M Tycko B Hibshoosh H Wigler MH Parsons R PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. 10.1126/science.275.5308.1943 9072974
50. Gymnopoulos M Elsliger MA Vogt PK Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007, 104:5569-5574. 1838453 17376864 10.1073/pnas.0701005104
51. Ikenoue T Kanai F Hikiba Y Obata T Tanaka Y Imamura J Ohta M Jazag A Guleng B Tateishi K Asaoka Y Matsumura M Kawabe T Omata M Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005, 65:4562-4567. 10.1158/0008-5472.CAN-04-4114 15930273
52. Campbell IG Russell SE Choong DY Montgomery KG Ciavarella ML Hooi CS Cristiano BE Pearson RB Phillips WA Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681. 10.1158/ 0008-5472.CAN-04-2933 15520168
53. Eisen MB Spellman PT Brown PO Botstein D Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 24541 9843981 10.1073/pnas.95.25.14863
54. Hall A Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005, 33:891-895. 10.1042/BST20050891 16246005
55. Shamah SM Lin MZ Goldberg JL Estrach S Sahin M Hu L Bazalakova M Neve RL Corfas G Debant A Greenberg ME EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 2001, 105:233-244. 10.1016/S0092-8674(01)00314-2 11336673
56. Huang M Prendergast GC RhoB in cancer suppression. Histol Histopathol 2006, 21:213-218. 16329046
57. Wheeler AP Ridley AJ Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004, 301:43-49. 10.1016/j.yexcr.2004.08.012 15501444
58. Mazieres J Antonia T Daste G Muro-Cacho C Berchery D Tillement V Pradines A Sebti S Favre G Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 2004, 10:2742-2750. 10.1158/ 1078-0432.CCR-03-0149 15102679
59. Coles LC Shaw PE PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene 2002, 21:2236-2244. 10.1038/sj.onc.1205302 11948406
60. Snijders AM Schmidt BL Fridlyand J Dekker N Pinkel D Jordan RC Albertson DG Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005, 24:4232-4242. 10.1038/sj.onc.1208601 15824737
61. Park ER Eblen ST Catling AD MEK1 activation by PAK: A novel mechanism. Cell Signal 2007, 19:1488-1496. 2233889 17314031 10.1016/ j.cellsig.2007.01.018
62. Ideker T Lauffenburger D Building with a scaffold: Emerging strategies for high- to low-level cellular modeling. Trends Biotechnol 2003, 21:255-262. 10.1016/S0167-7799(03)00115-X 12788545
63. Friedman N Linial M Nachman I Pe'er D Using Bayesian networks to analyze expression data. J Comput Biol 2000, 7:601-620. 10.1089/ 106652700750050961 11108481
64. Hartemink AJ Gifford DK Jaakkola TS Young RA Using graphical models and genomic expression data to statistically validate models of genetic regulatory networks. Pac Symp Biocomput 2001, 422-433. 11262961
65. Kholodenko BN Demin OV Moehren G Hoek JB Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999, 274:30169-30181. 10.1074/jbc.274.42.30169 10514507
66. Schoeberl B Eichler-Jonsson C Gilles ED Muller G Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 2002, 20:370-375. 10.1038/ nbt0402-370 11923843
67. Koh G Teong HF Clement MV Hsu D Thiagarajan PS A decompositional approach to parameter estimation in pathway modeling: A case study of the Akt and MAPK pathways and their crosstalk. Bioinformatics 2006, 22:e271. 280 10.1093/bioinformatics/btl264 16873482
68. Lincoln P Tiwari A Symbolic systems biology: Hybrid modeling and analysis of biological networks. Hybrid Systems: Computation and Control: 7th International Workshop, HSCC 2004: March 25-27, 2004; Philadelphia, PA, USA Springer: [Lecture Notes in Computer Science] Alur R, Pappas GJ 2004, 2993.
69. Dokholyan NV Shakhnovich B Shakhnovich EI Expanding protein universe and its origin from the biological Big Bang. Proc Natl Acad Sci USA 2002, 99:14132-14136. 137849 12384571 10.1073/pnas.202497999
70. Jeong H Tombor B Albert R Oltvai ZN Barabasi AL The large-scale organization of metabolic networks. Nature 2000, 407:651-654. 10.1038/ 35036627 11034217
71. Ishizawar R Parsons SJ c-Src and cooperating partners in human cancer. Cancer Cell 2004, 6:209-214. 10.1016/j.ccr.2004.09.001 15380511
72. Russello SV Shore SK Src in human carcinogenesis. Front Biosci 2003, 8:s1068-1073. 10.2741/1138 12957809
73. Benati D Baldari CT SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 2008, 15:1154-1165. 10.2174/092986708784310404 18473810
74. Johnson FM Gallick GE SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 2007, 7:651-659. 10.2174/187152007784111278 18045060
75. Jiang K Delarue FL Sebti SM EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004, 23:1136-1145. 10.1038/ sj.onc.1207236 14647415
76. Williams TM Hassan GS Li J Cohen AW Medina F Frank PG Pestell RG Di Vizio D Loda M Lisanti MP Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005, 280:25134-25145. 10.1074/jbc.M501186200 15802273
77. Williams TM Medina F Badano I Hazan RB Hutchinson J Muller WJ Chopra NG Scherer PE Pestell RG Lisanti MP Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/ 9) secretion. J Biol Chem 2004, 279:51630-51646. 10.1074/jbc.M409214200 15355971
78. Sells MA Boyd JT Chernoff J p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol 1999, 145:837-849. 2133181 10330410 10.1083/jcb.145.4.837
79. Sells MA Knaus UG Bagrodia S Ambrose DM Bokoch GM Chernoff J Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol 1997, 7:202-210. 10.1016/S0960-9822(97)70091-5 9395435
80. Balasenthil S Sahin AA Barnes CJ Wang RA Pestell RG Vadlamudi RK Kumar R p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary and cancer cells. J Biol Chem 2004, 279:1422-1428. 10.1074/ jbc.M309937200 14530270
81. Schurmann A Mooney AF Sanders LC Sells MA Wang HG Reed JC Bokoch GM p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000, 20:453-461. 85099 10611223 10.1128/MCB.20.2.453-461.2000
82. Carter JH Douglass LE Deddens JA Colligan BM Bhatt TR Pemberton JO Konicek S Hom J Marshall M Graff JR Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004, 10:3448-3456. 10.1158/1078-0432.CCR-03-0210 15161701
83. Schraml P Schwerdtfeger G Burkhalter F Raggi A Schmidt D Ruffalo T King W Wilber K Mihatsch MJ Moch H Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003, 163:985-992. 1868266 12937139
84. Wang RA Zhang H Balasenthil S Medina D Kumar R PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006, 25:2931-2936. 10.1038/sj.onc.1209309 16331248
85. Hanafusa H Torii S Yasunaga T Nishida E Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 2002, 4:850-858. 10.1038/ncb867 12402043
86. Roy F Laberge G Douziech M Ferland-McCollough D Therrien M KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev 2002, 16:427-438. 155344 11850406 10.1101/gad.962902
87. LBL Breast Cancer Website http://cancer.lbl.gov/breastcancer/data.php
88. Scion Image http://www.scioncorp.com/
89. LI-COR: Odyssey Software http://www.licor.com/
90. Irizarry RA Hobbs B Collin F Beazer-Barclay YD Antonellis KJ Scherf U Speed TP Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249 12925520
91. BioConductor http://www.bioconductor.org
92. UCSC Genome Browser http://genome.ucsc.edu/
93. Wang Y Moorhead M Karlin-Neumann G Wang NJ Ireland J Lin S Chen C Heiser LM Chin K Esserman L Gray JW Spellman PT Faham M Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol 2007, 8:R246. 2258201 18028543 10.1186/gb-2007-8-11-r246
94. O'Neill RA Bhamidipati A Bi X Deb-Basu D Cahill L Ferrante J Gentalen E Glazer M Gossett J Hacker K Kirby C Knittle J Loder R Mastroieni C Maclaren M Mills T Nguyen U Parker N Rice A Roach D Suich D Voehringer D Voss K Yang J Yang T Horn Vander PB Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA 2006, 103:16153-16158. 1618307 17053065 10.1073/pnas.0607973103
95. NCI/NIH DTP Human Tumor Cell Line Screen Process Website. http://dtp.nci.nih.gov/branches/btb/ivclsp.html
96. Monks A Scudiero D Skehan P Shoemaker R Paull K Vistica D Hose C Langley J Cronise P Vaigro-Wolff A Gray-Goodrich M Campbell H Mayo J Boyd M Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83:757-766. 10.1093/jnci/83.11.757 2041050
97. Pathway Logic http://pl.csl.sri.com
98. Peterson RJL Petri Nets: Properties, Analysis and Applications New Jersey: Prentice-Hall 1981.
99. Pollard KS Laan van der MJ A method to identify significant clusters in gene expression data. UC Berkeley Division of Biostatistics Working Paper Series. Working Paper 107, 2002. http://www.bepress.com/ucbbiostat/ paper107/
100. BioConductor Hopach Package Website http://www.bioconductor.org/packages/ 2.3/bioc/html/hopach.html
101. Saldanha AJ Java Treeview - extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248. 10.1093/bioinformatics/bth349 15180930